| 词条 | Pateclizumab |
| 释义 |
| Verifiedfields = changed | Watchedfields = changed | verifiedrevid = 458268914 | type = mab | image = | alt = | mab_type = mab | source = zu/o | target = lymphotoxin alpha | tradename = | Drugs.com = | MedlinePlus = | pregnancy_AU = | pregnancy_US = | pregnancy_category= | legal_AU = | legal_CA = | legal_UK = | legal_US = | legal_status = | routes_of_administration = | bioavailability = | protein_bound = | metabolism = | elimination_half-life = | excretion = | CAS_number_Ref = {{cascite|changed|??}} | CAS_number = 1202526-59-7 | ATC_prefix = none | ATC_suffix = | PubChem = | DrugBank_Ref = {{drugbankcite|correct|drugbank}} | DrugBank = | KEGG = D10187 | KEGG_Ref = {{keggcite|changed|kegg}} | ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}} | ChemSpiderID = none | C = 6436 | H = 9910 | N = 1710 | O = 2004 | S = 44 | molecular_weight = 144.7 kDa | synonyms = MLTA3698A }}Pateclizumab (MLTA3698A) is an immunomodulator. It binds to lymphotoxin alpha.[1][2][3][4][5][6] This drug was developed by Genentech/Roche. References1. ^{{cite journal | author = World Health Organization | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 105 | journal = WHO Drug Information | volume = 25 | issue = 2 | year = 2011 | url = http://www.who.int/medicines/publications/druginformation/innlists/Final_PL105.pdf | format = PDF }}{{dead link|date=March 2018 |bot=InternetArchiveBot |fix-attempted=yes }} {{Monoclonals for immune system}}{{Chemokine receptor modulators}}{{monoclonal-antibody-stub}}{{antineoplastic-drug-stub}}2. ^Statement On A Nonproprietary Name Adopted By The USAN Council - Pateclizumab, American Medical Association. 3. ^{{cite journal |vauthors=Kennedy WP, Simon JA, Offutt C, Horn P, Herman A, Townsend MJ, Tang MT, Grogan JL, Hsieh F, Davis JC |title=Efficacy and safety of pateclizumab (anti-lymphotoxin-α) compared to adalimumab in rheumatoid arthritis: a head-to-head phase 2 randomized controlled study (The ALTARA Study) |journal=Arthritis Res. Ther. |volume=16 |issue=5 |pages=467 |date=October 2014 |pmid=25359150 |pmc=4243296 |doi=10.1186/s13075-014-0467-3 |url=}} 4. ^{{cite journal |vauthors=Emu B, Luca D, Offutt C, Grogan JL, Rojkovich B, Williams MB, Tang MT, Xiao J, Lee JH, Davis JC |title=Safety, pharmacokinetics, and biologic activity of pateclizumab, a novel monoclonal antibody targeting lymphotoxin α: results of a phase I randomized, placebo-controlled trial |journal=Arthritis Res. Ther. |volume=14 |issue=1 |pages=R6 |date=January 2012 |pmid=22225620 |pmc=3392792 |doi=10.1186/ar3554 |url=}} 5. ^{{cite journal |vauthors=Wang H, Schuetz C, Arima A, Chihaya Y, Weinbauer GF, Habermann G, Xiao J, Woods C, Grogan J, Gelzleichter T, Cain G |title=Assessment of placental transfer and the effect on embryo-fetal development of a humanized monoclonal antibody targeting lymphotoxin-alpha in non-human primates |journal=Reprod. Toxicol. |volume=63 |issue= |pages=82–95 |date=August 2016 |pmid=27211603 |doi=10.1016/j.reprotox.2016.05.014 |url=}} 6. ^{{cite journal |vauthors=Hirose T, Fukuma Y, Takeshita A, Nishida K |title=The role of lymphotoxin-α in rheumatoid arthritis |journal=Inflamm. Res. |volume=67 |issue=6 |pages=495–501 |date=June 2018 |pmid=29541795 |doi=10.1007/s00011-018-1139-6 |url=}} 1 : Monoclonal antibodies |
| 随便看 |
|
开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。